Real Life Analysis of new PPAR agonists for treatment of PBC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038209

Enrollment

Registered

2026-01-06

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K74.3

Interventions

Group 1: PBC patients treated with Elafibranor or Seladelpar Documentation of laboratory values/therapy 1 year before switching, when switching to Elafibranor/Seladelpar and thereafter in all availab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: PBC diagnosis and second line treatment with PPAR agonists

Exclusion criteria

Exclusion criteria: Liver transplant, AIH

Design outcomes

Primary

Measure	Time frame
AP normalisation	—

Secondary

Measure	Time frame
Response following Paris II criteria	—

Countries

Germany

Contacts

Public ContactAlexander Killer

Uniklinik Düsseldorf

alexander.killer@med.uni-duesseldorf.de02118105465

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026